

# Topical Collection

## Poorly Soluble Drugs

### Message from the Collection Editors

Increasingly important bottlenecks for the development of medicines result from the poor aqueous solubilities and low dissolution rates of many small molecular weight drugs in the pipelines of pharmaceutical companies. To increase the solubilities and dissolution rates of drugs, and thus their bioavailabilities, several feasible approaches can be taken, and are of special interest, both in academia, and in the pharmaceutical industry. These include the conversion of crystalline drugs to their respective amorphous forms, the use of lipid based drug delivery systems, particle size reduction, salt-, co-crystal, and pro-drug formations, and the use of cyclodextrin complexes, to name but a few. This Special Issue aims to provide a forum for the dissemination of the latest information on new approaches and methods for dealing with poorly soluble drugs, and with methods of testing their success.

---

### Collection Editors


Prof. Dr. Guy Van den Mooter

Prof. Dr. Korbinian Löbmann

Prof. Dr. Thomas Rades

Prof. Dr. Holger Grohgan

---



## Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/si/4527](https://mdpi.com/si/4527)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).